Literature DB >> 20231060

External beam radiotherapy with endocavitary boost for nasopharyngeal cancer: treatment results and late toxicity after extended follow-up.

Dominic A X Schinagl1, Henri A M Marres, Arnoud C Kappelle, Matthias A W Merkx, Lucas A M Pop, Suzan M M Verstappen, Johannes H A M Kaanders.   

Abstract

PURPOSE: To evaluate the long-term outcome after treatment of nasopharyngeal carcinoma and assess late toxicity in a multidisciplinary clinic. METHODS AND MATERIALS: A retrospective analysis of 117 patients treated for nasopharyngeal cancer in a single institute between 1985 and 2002 was performed. Fifty-one long-term survivors were evaluated for late toxicity by a multidisciplinary team comprising a radiation oncologist, otolaryngologist, neurologist, and oral and maxillofacial surgeon.
RESULTS: The 5-year local control rate for T1 to T2 and T3 to T4 tumors was 97% and 76%, respectively. Five-year disease-free survival and overall survival were 82% and 88% for Stage I to IIb disease and 46% and 52% for Stage III to IVb, respectively. Late morbidity evaluation revealed Radiation Therapy Oncology Group (RTOG) Grade III to IV toxicity in 71% of patients. A high incidence of cranial nerve palsies (47%) and mandibular osteolysis (82%) was found, although these complications had limited clinical impact.
CONCLUSIONS: The multidisciplinary late morbidity clinic revealed an unexpected high incidence of cranial nerve palsies and mandibular osteolysis and overall an RTOG Grade III to IV toxicity in 71% of patients treated for nasopharyngeal cancer. External beam radiotherapy with endocavitary brachytherapy produces excellent rates of local control for T1 to T2 tumors, but the high incidence of late toxicity suggests an overtreatment.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20231060     DOI: 10.1016/j.ijrobp.2009.08.072

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review.

Authors:  Katherine A Hutcheson; Maggie Yuk; Rachel Hubbard; Gary B Gunn; C David Fuller; Stephen Y Lai; Heather Lin; Adam S Garden; David I Rosenthal; Ehab Y Hanna; Merrill S Kies; Jan S Lewin
Journal:  Head Neck       Date:  2017-04-28       Impact factor: 3.147

2.  Review of photon and proton radiotherapy for skull base tumours.

Authors:  Piero Fossati; Andrea Vavassori; Letizia Deantonio; Eleonora Ferrara; Marco Krengli; Roberto Orecchia
Journal:  Rep Pract Oncol Radiother       Date:  2016-04-16

3.  Nasopharyngeal carcinoma in Slovenia, 1990-2003 (results of treatment with conventional two-dimensional radiotherapy).

Authors:  Janka Carman; Primož Strojan
Journal:  Rep Pract Oncol Radiother       Date:  2012-03-06

4.  Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.

Authors:  Xiaomin Ou; Xin Zhou; Qi Shi; Xing Xing; Youqi Yang; Tingting Xu; Chunying Shen; Xiaoshen Wang; Xiayun He; Lin Kong; Hongmei Ying; Chaosu Hu
Journal:  Oncotarget       Date:  2015-11-10

5.  Local regression and control of T1-2 nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Authors:  Fen Xue; Dan Ou; Chaosu Hu; Xiayun He
Journal:  Cancer Med       Date:  2018-11-08       Impact factor: 4.452

6.  Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study.

Authors:  Ning Zhang; Shao-Bo Liang; Yan-Ming Deng; Rui-Liang Lu; Hai-Yang Chen; Hai Zhao; Zhi-Qian Lv; Shao-Qiang Liang; Lin Yang; Dong-Sheng Liu; Yong Chen
Journal:  BMC Cancer       Date:  2014-02-27       Impact factor: 4.430

7.  Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma.

Authors:  Xiang-Bo Wan; Rou Jiang; Fang-Yun Xie; Zhen-Yu Qi; Ai-Ju Li; Wei-Jun Ye; Yi-Jun Hua; Yu-Liang Zhu; Xiong Zou; Ling Guo; Hai-Qiang Mai; Xiang Guo; Ming-Huang Hong; Ming-Yuan Chen
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.